GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Additional Paid-In Capital

BridgeBio Pharma (FRA:2CL) Additional Paid-In Capital : €1,719.6 Mil(As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Additional Paid-In Capital?


BridgeBio Pharma's quarterly additional paid-in capital increased from Dec. 2023 (€1,358.1 Mil) to Mar. 2024 (€1,675.3 Mil) and increased from Mar. 2024 (€1,675.3 Mil) to Jun. 2024 (€1,719.6 Mil).

BridgeBio Pharma's annual additional paid-in capital increased from Dec. 2021 (€744.8 Mil) to Dec. 2022 (€886.1 Mil) and increased from Dec. 2022 (€886.1 Mil) to Dec. 2023 (€1,358.1 Mil).


BridgeBio Pharma Additional Paid-In Capital Historical Data

The historical data trend for BridgeBio Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Additional Paid-In Capital Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 763.30 839.55 744.75 886.14 1,358.11

BridgeBio Pharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,041.24 1,367.64 1,358.11 1,675.31 1,719.63

BridgeBio Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

BridgeBio Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma Headlines

No Headlines